IOVANCE BIOTHERAPEUTICS ($IOVA) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of -$0.11 per share, beating estimates of -$0.13 by $0.02. The company also reported revenue of $99,310,000, beating estimates of $89,426,796 by $9,883,204.
You can see Quiver Quantitative's $IOVA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IOVANCE BIOTHERAPEUTICS Hedge Fund Activity
We have seen 158 institutional investors add shares of IOVANCE BIOTHERAPEUTICS stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP added 9,289,444 shares (+211.2%) to their portfolio in Q1 2026, for an estimated $32,605,948
- LONG FOCUS CAPITAL MANAGEMENT, LLC removed 6,500,000 shares (-75.6%) from their portfolio in Q1 2026, for an estimated $22,815,000
- BANK OF AMERICA CORP /DE/ removed 5,787,694 shares (-40.5%) from their portfolio in Q1 2026, for an estimated $20,314,805
- INVENOMIC CAPITAL MANAGEMENT LP removed 3,463,954 shares (-29.0%) from their portfolio in Q1 2026, for an estimated $12,158,478
- MORGAN STANLEY removed 2,990,558 shares (-32.5%) from their portfolio in Q1 2026, for an estimated $10,496,858
- MILLENNIUM MANAGEMENT LLC added 2,828,760 shares (+43.0%) to their portfolio in Q1 2026, for an estimated $9,928,947
- STATE STREET CORP removed 2,713,337 shares (-13.5%) from their portfolio in Q1 2026, for an estimated $9,523,812
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
IOVANCE BIOTHERAPEUTICS Price Targets
Multiple analysts have issued price targets for $IOVA recently. We have seen 4 analysts offer price targets for $IOVA in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $14.0 on 05/07/2026
- David Dai from UBS set a target price of $4.0 on 03/05/2026
- Reni J. Benjamin from Citizens set a target price of $5.0 on 03/03/2026
- Etzer Darout from Barclays set a target price of $11.0 on 02/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
